Effects of nicotine and minor tobacco alkaloids on intracranial-self-stimulation in rats

Drug and Alcohol Dependence

Volumn 153, Issue , 2015, Pages 330-334

  Harris, Andrew C ^a,b,c   Tally, Laura ^a   Muelken, Peter ^a,c   Banal, Andrew ^a,c   Schmidt, Clare E ^a,c   Cao, Qing ^d   LeSage, Mark G ^a,b,c  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Intracranial self stimulation; Minor alkaloids; Nicotine; Non nicotine tobacco constituents; Rat

Indexed keywords

ALKALOID; ANABASINE; ANATABINE; MYOSMINE; NICOTINE; NORNICOTINE; TOBACCO ALKALOID; UNCLASSIFIED DRUG; COTININE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; FOOD AND DRUG ADMINISTRATION; LATENT PERIOD; MALE; MOTOR ACTIVITY; NONHUMAN; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; RAT; REINFORCEMENT; SELF STIMULATION; SMOKING REGULATION; STIMULUS RESPONSE; TOBACCO DEPENDENCE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; DRUG EFFECTS; PHYSIOLOGY;

NICOTIANA TABACUM; RATTUS;

ALKALOIDS; ANABASINE; ANIMALS; BRAIN; COTININE; MALE; NICOTINE; PYRIDINES; RATS; SELF STIMULATION;

EID: 84937630045     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.06.005     Document Type: Article

References (47)

1. Arnold M.M., Loughlin S.E., Belluzzi J.D., Leslie F.M. Reinforcing and neural activating effects of norharmane, a non-nicotine tobacco constituent, alone and in combination with nicotine. Neuropharmacology 2014, 85:293-304.
2. Bardo M.T., Green T.A., Crooks P.A., Dwoskin L.P. Nornicotine is self-administered intravenously by rats. Psychopharmacology 1999, 146:290-296.
3. Belluzzi J.D., Wang R., Leslie F.M. Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 2005, 30:705-712.
4. Benowitz N.L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 2008, 83:531-541.
5. Benowitz N.L., Henningfield J.E. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N. Engl. J. Med. 1994, 331:123-125.
6. Benowitz N.L., Henningfield J.E. Reducing the nicotine content to make cigarettes less addictive. Tob. Control 2013, 22(Suppl. 1):i14-i17.
7. Brennan K.A., Laugesen M., Truman P. Whole tobacco smoke extracts to model tobacco dependence in animals. Neurosci. Biobehav. Rev. 2014, 47C:53-69.
8. Caggiula A.R., Donny E.C., Palmatier M.I., Liu X., Chaudhri N., Sved A.F. The role of nicotine in smoking: a dual-reinforcement model. Nebr. Symp. Motiv. 2009, 55:91-109.
9. Caine S.B., Collins G.T., Thomsen M., Wright C., Lanier R.K., Mello N.K. Nicotine-like behavioral effects of the minor tobacco alkaloids nornicotine, anabasine, and anatabine in male rodents. Exp. Clin. Psychopharmacol. 2014, 22:9-22.
10. Chaudhri N., Caggiula A.R., Donny E.C., Palmatier M.I., Liu X., Sved A.F. Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology 2006, 184:353-366.
11. Clemens K.J., Caille S., Stinus L., Cador M. The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats. Int. J. Neuropsychopharmacol. 2009, 12:1355-1366.
12. Deyton L., Sharfstein J., Hamburg M. Tobacco product regulation - a public health approach. N. Engl. J. Med. 2010, 362:1753-1756.
13. Dwoskin L.P., Crooks P.A., Teng L., Green T.A., Bardo M.T. Acute and chronic effects of nornicotine on locomotor activity in rats: altered response to nicotine. Psychopharmacology 1999, 145:442-451.
14. Food and Drug Administration Harmful and potentially harmful constituents in tobacco products and tobacco smoke: established list. Fed. Regist. 2012, 77:20034-20037.
15. Fowler C.D., Kenny P.J. Nicotine aversion: neurobiological mechanisms and relevance to tobacco dependence vulnerability. Neuropharmacology 2013, 76:533-544.
16. Fowler C.D., Lu Q., Johnson P.M., Marks M.J., Kenny P.J. Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature 2011, 471:597-601.
17. Goldberg S.R., Risner M.E., Stolerman I.P., Reavill C., Garcha H.S. Nicotine and some related compounds: effects on schedule-controlled behaviour and discriminative properties in rats. Psychopharmacology 1989, 97:295-302.
18. Green T.A., Phillips S.B., Crooks P.A., Dwoskin L.P., Bardo M.T. Nornicotine pretreatment decreases intravenous nicotine self-administration in rats. Psychopharmacology 2000, 152:289-294.
19. Hall B.J., Wells C., Allenby C., Lin M.Y., Hao I., Marshall L., Rose J.E., Levin E.D. Differential effects of non-nicotine tobacco constituent compounds on nicotine self-administration in rats. Pharmacol. Biochem. Behav. 2014, 120:103-108.
20. Harris A.C., Mattson C., Lesage M.G., Keyler D.E., Pentel P.R. Comparison of the behavioral effects of cigarette smoke and pure nicotine in rats. Pharmacol. Biochem. Behav. 2010, 96:217-227.
21. Harris A.C., Pentel P.R., Burroughs D., Staley M.D., Lesage M.G. A lack of association between severity of nicotine withdrawal and individual differences in compensatory nicotine self-administration in rats. Psychopharmacology 2011, 217:153-166.
22. Harris A.C., Manbeck K.E., Schmidt C.E., Shelley D. Mecamylamine elicits withdrawal-like signs in rats following a single dose of nicotine. Psychopharmacology 2013, 225:291-302.
23. Harris A.C., Tally L., Schmidt C.E., Muelken P., Stepanov I., Saha S., Vogel R.I., LeSage M.G. Animal models to assess the abuse liability of tobacco products: effects of smokeless tobacco extracts on intracranial self-stimulation. Drug Alcohol Depend. 2015, 147:60-67.
24. Harrison A.A., Gasparini F., Markou A. Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology 2002, 160:56-66.
25. Hatsukami D.K., Perkins K.A., Lesage M.G., Ashley D.L., Henningfield J.E., Benowitz N.L., Backinger C.L., Zeller M. Nicotine reduction revisited: science and future directions. Tob. Control 2010, 19:e1-e10.
26. Hatsukami D.K., Benowitz N.L., Donny E., Henningfield J., Zeller M. Nicotine reduction: strategic research plan. Nicotine Tob. Res. 2012, 15:2003-2013.
27. Henningfield J.E., Benowitz N.L., Connolly G.N., Davis R.M., Gray N., Myers M.L., Zeller M. Reducing tobacco addiction through tobacco product regulation. Tob. Control 2004, 13:132-135.
28. Hoffman A.C., Evans S.E. Abuse potential of non-nicotine tobacco smoke components: acetaldehyde, nornicotine, cotinine, and anabasine. Nicotine Tob. Res. 2013, 15:622-632.
29. Huston-Lyons D., Kornetsky C. Effects of nicotine on the threshold for rewarding brain stimulation in rats. Pharmacol. Biochem. Behav. 1992, 41:755-759.
30. Kenny P.J., Polis I., Koob G.F., Markou A. Low dose cocaine self-administration transiently increases but high dose cocaine persistently decreases brain reward function in rats. Eur. J. Neurosci. 2003, 17:191-195.
31. Kornetsky C., Esposito R.U. Euphorigenic drugs: effects on the reward pathways of the brain. Fed. Proc. 1979, 38:2473-2476.
32. Manbeck K.E., Shelley D., Schmidt C.E., Harris A.C. Effects of oxytocin on nicotine withdrawal in rats. Pharmacol. Biochem. Behav. 2013, 116C:84-89.
33. Markou A., Koob G.F. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 1991, 4:17-26.
34. Markou A., Koob G.F. Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol. Behav. 1992, 51:111-119.
35. National Research Council Guidelines for the care and use of mammals in neuroscience and behavioral research 2003, The National Academies, Washington, DC.
36. Paterson N.E. The neuropharmacological substrates of nicotine reward: reinforcing versus reinforcement-enhancing effects of nicotine. Behav. Pharmacol. 2009, 20:211-225.
37. Paterson N.E., Balfour D.J., Markou A. Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats. Nicotine Tob. Res. 2008, 10:995-1008.
38. Pratt J.A., Stolerman I.P., Garcha H.S., Giardini V., Feyerabend C. Discriminative stimulus properties of nicotine: further evidence for mediation at a cholinergic receptor. Psychopharmacology 1983, 81:54-60.
39. Spiller K., Xi Z.X., Li X., Ashby C.R., Callahan P.M., Tehim A., Gardner E.L. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats. Neuropharmacology 2009, 57:60-66.
40. Stolerman I.P., Garcha H.S., Pratt J.A., Kumar R. Role of training dose in discrimination of nicotine and related compounds by rats. Psychopharmacology 1984, 84:413-419.
41. Stolerman I.P., Garcha H.S., Mirza N.R. Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychopharmacology 1995, 117:430-437.
42. U.S. Public Health Service The Health Consequences Of Smoking: Nicotine Addiction: A Report Of The Surgeon General 1988, U.S. Department of Health and Human Services, Washington, DC.
43. Verendeev A., Riley A.L. The role of the aversive effects of drugs in self-administration: assessing the balance of reward and aversion in drug-taking behavior. Behav. Pharmacol. 2013, 24:363-374.
44. Wiley J.L., Marusich J.A., Thomas B.F., Jackson K.J. Determination of behaviorally effective tobacco constituent doses in rats. Nicotine Tob. Res. 2015, 17:368-371.
45. Wise R.A. Addictive drugs and brain stimulation reward. Annu. Rev. Neurosci. 1996, 19:319-340.
46. Wise R.A. Brain reward circuitry: insights from unsensed incentives. Neuron 2002, 36:229-240.
47. Wise R.A., Bauco P., Carlezon W.A., Trojniar W. Self-stimulation and drug reward mechanisms. Ann. N. Y. Acad. Sci. 1992, 654:192-198.